BioMEMS Market size is expected to gain significant momentum through 2027 led by emerging applications of microtechnology in medicine, life sciences, and other areas. The recent upsurge in home care and remote monitoring in wake of the global COVID-19 pandemic has created promising opportunities for BioMEMS adoption.
BioMEMS (biological microelectromechanical systems) include a range of sensors and microfluidic devices which are integrated into medical devices. The technology is fast emerging as the platform for delivery of future nanotechnologies such as encapsulated drug delivery systems, stem cell research, and others.
BioMEMS are utilized in therapeutic, diagnostic, tissue engineering, and other life science applications. BioMEMS industry share from diagnostic segment is slated to expand substantially by the end of 2027. Different types of microelectromechanical technologies are being increasingly used for diagnostic applications including disease identification, antibody identification, and protein isoform identification, among others.
In terms of the end-user, the food and agriculture sector is poised to capture a majority of the BioMEMS market share by 2027. While majority of R&D efforts in the industry have been focused on medical and life science applications, use of BioMEMS in food and agricultural sector is growing steadily.
The food industry is currently facing two key challenges: providing enough food for the burgeoning global population; and ensuring the safety of food products by controlling the occurrence of outbreaks. Recent advances in BioMEMS research have shown promise for the development of sensing systems for detection of biological and chemical agents even at extremely low concentrations. The adoption of rapid, accurate, and cost-effective detection technologies such as BioMEMS can help control and reduce food contamination and food waste drastically.
Considering geography, North America BioMEMS industry size is likely to witness robust expansion through 2027, led by the penetration of medical device manufacturers in the region. Ongoing technological advances and growing automation in various end-use sectors is creating more opportunities for BioMEMS deployment. An established healthcare infrastructure and rapid adoption of novel medical technologies will certainly bolster the regional industry outlook.
Boston Scientific, Cepheid, Becton, Dickinson and Company (BD), Teledyne DALSA, Micron Technology, OMRON, MEC Company LTD., United Gene High-Tech Group, Given Imaging and Integrated Sensing Systems, Bluechiip, Nanopass Technologies, Lepu Medical Technology, CapitalBio Corporation, and Heimann Sensor are some of the notable BioMEMS companies worldwide.
Advances in tissue engineering, drug delivery systems, diagnostics, therapeutics, and other areas are constantly driving new innovations in the BioMEMS market. Market players are actively investing in research and development to introduce new, advanced technologies to the market. Numerous manufacturers are also adopting growth strategies such as acquisitions, partnerships, and capacity expansion to strengthen their position in the industry.
Wearables, connected medical devices, and remote monitoring devices are gathering more attention from the healthcare sector as the COVID-19 pandemic continues to affect economies. Throughout the pandemic year, BioMEMS technologies experienced demand in respiratory devices and equipment which had faced massive shortage in several regions. The continued use of connected technologies and remote patient care even after the pandemic will augment BioMEMS market trends over 2021-2027.